癌症研究——整体能大于部分之和吗?

Oncoscience Pub Date : 2020-05-01 eCollection Date: 2020-03-01 DOI:10.18632/oncoscience.499
Georg F Weber
{"title":"癌症研究——整体能大于部分之和吗?","authors":"Georg F Weber","doi":"10.18632/oncoscience.499","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer Research has benefitted from substantial expenditures by federal and nonprofit organizations. The resulting success in patient care has been uneven. Two lessons from the 20<sup>th</sup> century history of science suggest infrastructural changes that can boost success. We need to better organize big science, explicitly aiming for expedient clinical translation. In parallel, resource allocation should enable investigator-initiated exploration on the basis of productivity per research dollars spent.</p>","PeriodicalId":19508,"journal":{"name":"Oncoscience","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217137/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cancer research - can the entity be bigger than the sum of its parts?\",\"authors\":\"Georg F Weber\",\"doi\":\"10.18632/oncoscience.499\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer Research has benefitted from substantial expenditures by federal and nonprofit organizations. The resulting success in patient care has been uneven. Two lessons from the 20<sup>th</sup> century history of science suggest infrastructural changes that can boost success. We need to better organize big science, explicitly aiming for expedient clinical translation. In parallel, resource allocation should enable investigator-initiated exploration on the basis of productivity per research dollars spent.</p>\",\"PeriodicalId\":19508,\"journal\":{\"name\":\"Oncoscience\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217137/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18632/oncoscience.499\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/oncoscience.499","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/3/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

癌症研究从联邦和非营利组织的大量支出中受益。在病人护理方面取得的成功参差不齐。20世纪科学史的两个教训表明,基础设施的改变可以促进成功。我们需要更好地组织大科学,明确针对权宜之计的临床翻译。与此同时,资源分配应使研究人员能够根据每一研究经费的生产率发起探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cancer research - can the entity be bigger than the sum of its parts?

Cancer Research has benefitted from substantial expenditures by federal and nonprofit organizations. The resulting success in patient care has been uneven. Two lessons from the 20th century history of science suggest infrastructural changes that can boost success. We need to better organize big science, explicitly aiming for expedient clinical translation. In parallel, resource allocation should enable investigator-initiated exploration on the basis of productivity per research dollars spent.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone Cancer drug development yesterday, today and tomorrow. Adenoid cystic carcinoma of the head and neck - treatment strategies of a highly malignant tumor with variable localizations. Kinase-targeted therapy in subsets of colorectal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1